<DOC>
	<DOCNO>NCT00071461</DOCNO>
	<brief_summary>Endothelin-1 ( ET-1 ) express variety pulmonary pathological condition include pulmonary vascular disease pulmonary fibrosis . Bosentan ( oral dual ET-1 receptor antagonist ) could delay progression idiopathic pulmonary fibrosis ( IPF ) , condition establish treatment available . The present trial investigates possible use bosentan , currently approve treatment symptom pulmonary arterial hypertension ( PAH ) WHO class III IV , new category patient suffer IPF . It decide offer Open Label treatment ( bosentan ) patient willing continue BUILD 1 study .</brief_summary>
	<brief_title>Efficacy Safety Oral Bosentan Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Male female patient 18 year age . Women must either postmenopausal ( i.e. , amenorrhea least 1 year ) , surgically naturally sterile . Women childbearing potential must negative pretreatment pregnancy test use reliable method contraception study treatment least 3 month study treatment termination . 2 . IPF proven diagnosis &lt; 3 year document accord ATS/ERS international multidisciplinary consensus , without surgical ( thoracoscopic open ) chest lung biopsy 3 . Duration illness ≥ 3 month . 4 . Sixminute walk test distance ( limited dyspnea ) ≥ 150 meter &lt; 500 meter 5 . Patients sign informed consent form prior initiation study procedure . 1 . Interstitial lung disease due condition IPF , include limited radiation , sarcoidosis , hypersensitivity pneumonitis , bronchiolitis obliterans organize pneumonia , cancer . 2 . History clinically significant environmental exposure know cause pulmonary fibrosis ( drug , asbestos , beryllium , radiation , domestic bird , etc. ) . 3 . Severe concomitant illness limit life expectancy ( &lt; 1 year ) . 4 . FVC ≥ 90 % predict . 5 . Severe restrictive lung disease : FVC &lt; 50 % predict FVC &lt; 1.2 l , DLco &lt; 30 % predict residual volume ≥ 120 % predict . 6 . Severe obstructive lung disease : FEV1/FVC &lt; 0.65 . 7 . Documented improvement patient 's condition within 12 month prior randomization without IPFspecific therapy ( e.g. , corticosteroid , immunosuppressive , cytotoxic antifibrotic drug , TNFa blocker , interferon g ) . 8 . Recent pulmonary upper respiratory track infection ( within 4 week randomization ) . 9 . PaO2 &lt; 55 mm Hg ( sea level ) 50 mm Hg ( altitude ) rest room air . 10 . Echocardiographic evidence severe pulmonary hypertension ( PH ) : systolic pulmonary pressure ≥ 50 mm Hg tricuspid regurgitation velocity ≥ 3.2 m/sec ( unless severe PH invalidate right heart catheterization ) . If pulmonary pressure quantifiable , presence significant right ventricular enlargement hypertrophy right ventricular dysfunction . 11 . Severe chronic heart failure , e.g. , NYHA class III IV and/or leave ventricular ejection fraction &lt; 25 % . 12 . Acute chronic impairment ( dyspnea ) limit ability comply study requirement , e.g. , 6MWT PFTs . ( e.g. , angina pectoris , intermittent claudicating , chronic arthritis ) . 13 . Baseline value liver transaminase , i.e. , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal range . 14 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. 15 . Serum creatinine ≥ 2.5 mg/dl ( 221 mmol/l ) dialysis . 16 . Hemoglobin concentration &lt; 75 % low limit normal range . 17 . Systolic blood pressure &lt; 85 mm Hg . 18 . Pregnancy breastfeed . 19 . Current drug alcohol dependence . 20 . Smoker ( ≥ 5 cigarette per day ) former smoker ( ≥ 5 cigarette per day ) stop less 6 month prior randomization . 21 . Recently start ( &lt; 8 week Screening visit ) plan cardiopulmonary rehabilitation program base exercise . 22 . Treatment oral corticosteroid ( &gt; 15 mg/day prednisone equivalent ) , immunosuppressive , cytotoxic antifibrotic drug TNF alpha blocker , interferon gamma within 4 week randomization.within 4 week randomization . 23 . Treatment glibenclamide ( glyburide ) , cyclosporine A tacrolimus within 1 week randomization . 24 . Treatment endothelin receptor antagonist within 3 month randomization . 25 . Treatment within 3 month randomization plan treatment another investigational drug . 26 . Known hypersensitivity bosentan excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Bosentan</keyword>
	<keyword>BUILD</keyword>
</DOC>